

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Connecticut Imaging Partners, LLC</p> <p>2. 111 Founders Plaza, Suite 400 East Hartford, CT 06108</p>	<p>In accordance with letter dated February 22, 2018.</p> <p>3. License number: 06-28502-01 is amended in its entirety to read as follows:</p>
	<p>4. Expiration Date: December 31, 2025</p> <p>5. Docket No.: 030-31642 Reference No.:</p>

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 750 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.</p>
--	---	---	--

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at: 704 Hebron Avenue, Suite 101, Glastonbury, Connecticut, 06033

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
06-28502-01

Amendment No. 24

Docket or Reference Number
030-31642

11. The Radiation Safety Officer (RSO) for this license is Ronald J Rosenberg, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)

Material and Use

Bruce P. Arose, M.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Thomas H. Farquhar, M.D., Ph.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Brian J. Grogan, M.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Joanna E. Jacunski, M.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Prasanta K. Karak, M.D.	10 CFR 35.100, 10 CFR 35.200
Angabeen S. Khan	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131
Jennifer C. Logan, M.D.	10 CFR 35.100, 10 CFR 35.200
Michael T. O'Loughlin, M.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
John Opalacz, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Ruben Rock, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Ronald J. Rosenberg, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Gregory T. Turner, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Steven R. Urbanski, M.D.	10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-28502-01

Amendment No. 24


Docket or Reference Number
030-31642

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 17, 2015 (except, Farmington site) [ML15190A181]
 - B. Letter dated December 10, 2015 (except, Farmington site) [ML15355A447]
 - C. Letters dated February 22 & 26, 2018 [ML18082B0665]
 - D. Letter dated May 29, 2018 [ML19025A040]

Date: February 1, 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By:



Donna M. Janda
Region 1